VT Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
← catalyst calendarNCT06384599 · readout in 255 d
Sponsored by Adagio Medical (industry) · ADGM — their whole pipeline →.
Phase
Not applicable
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
130estimated
Sites
1
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-01 | estimated | When the study began enrolling |
| Primary completion | 2027-05-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ventricular Tachycardia
Intervention
- Device: VT Cryoablation System
Primary outcomes
what the primary-completion date above is the date OFPrimary Performance Endpoint
measured 6 months
Primary Safety Endpoint
measured 30 Days
Permalink · ADGM's whole pipeline · Catalyst calendar · Every registered study · What changed